Manuel Baca

Manuel Baca

Auto-generated profile, based on publicly available information

Manuel Baca

Biol Engn, R&D, AstraZeneca, Gaithersburg, MD USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2022 in Science Immunology
Verified
Journal Article
Closed access
VFValeria Fumagalli
Valeria Fumagalli
VVValentina Venzin
Valentina Venzin
PLPietro Di Lucia
Pietro Di Lucia
FMFederica Moalli
Federica Moalli
XFXenia Ficht
Xenia Ficht
MIMatteo Iannacone
Matteo Iannacone
Group 1 innate lymphoid cells (ILCs), which comprise both natural killer (NK) cells and ILC1s, are important innate effectors that can also positively and negatively influence adaptive immune responses. The latter function is generally ascribed to the ability of NK cells to recognize and kill activated T cells. Here, we used multiphoton intravital microscopy in mouse models of hepatitis B to study the intrahepatic behavior of group 1 ILCs and their cross-talk with hepatitis B virus (HBV)–specific CD8 + T cells. We found that hepatocellular antigen recognition by effector CD8 + T cells triggered a prominent increase in the number of hepatic NK cells and ILC1s. Group 1 ILCs colocalized and engaged in prolonged interactions with effector CD8 + T cells undergoing hepatocellular antigen recognition; however, they did not induce T cell apoptosis. Rather, group 1 ILCs constrained CD8 + T cell proliferation by controlling local interleukin-2 (IL-2) availability. Accordingly, group 1 ILC depletion, or genetic removal of their IL-2 receptor a chain, considerably increased the number of intrahepatic HBV-specific effector CD8 + T cells and the attendant immunopathology. Together, these results reveal a role for group 1 ILCs in controlling T cell–mediated liver immunopathology by limiting local IL-2 concentration and have implications for the treatment of chronic HBV infection.

28 March 2013 in Biochemical Journal
Verified
Journal Article
Open access
PDF file
NRNicholas T. Redpath
Nicholas T. Redpath
YXYibin Xu
Yibin Xu
NWNicholas J. Wilson
Nicholas J. Wilson
LFLouis J. Fabri
Louis J. Fabri
MBManuel Baca
Manuel Baca
NNNicos A. Nicola
Nicos A. Nicola
Gene deletion studies in mice have revealed critical roles for IL (interleukin)-4 and -13 in asthma development, with the latter controlling lung airways resistance and mucus secretion. We have now developed human neutralizing monoclonal antibodies against human IL-13Rα1 (IL-13 receptor α1) subunit that prevent activation of the receptor complex by both IL-4 and IL-13. We describe the crystal structures of the Fab fragment of antibody 10G5H6 alone and in complex with D3 (ectodomain 3) of IL-13Rα1. Although the structure showed significant domain swapping within a D3 dimer, we showed that Arg230, Phe233, Tyr250, Gln252 and Leu293 in each D3 monomer and Ser32, Asn102 and Trp103 in 10G5H6 Fab are the key interacting residues at the interface of the 10G5H6 Fab–D3 complex. One of the most striking contacts is the insertion of the ligand-contacting residue Leu293 of D3 into a deep pocket on the surface of 10G5H6 Fab, and this appears to be a central determinant of the high binding affinity and neutralizing activity of the antibody.

21 October 2023 in Journal of Biological Chemistry
Verified
Journal Article
Open access
DVDerek VanDyke
Derek VanDyke
LXLinda Xu
Linda Xu
PSPaul R. Sargunas
Paul R. Sargunas
RGRyan N. Gilbreth
Ryan N. Gilbreth
MBManuel Baca
Manuel Baca
JSJamie B. Spangler
Jamie B. Spangler
Hijacking the ubiquitin proteasome system to elicit targeted protein degradation (TPD) has emerged as a promising therapeutic strategy to target and destroy intracellular proteins at the post-translational level. Small molecule-based TPD approaches, such as proteolysis-targeting chimeras (PROTACs) and molecular glues, have shown potential, with several agents currently in clinical trials. Biological PROTACs (bioPROTACs), which are engineered fusion proteins comprised of a target-binding domain and an E3 ubiquitin ligase, have emerged as a complementary approach for TPD. Here, we describe a new method for the evolution and design of bioPROTACs. Specifically, engineered binding scaffolds based on the third fibronectin type III domain of human tenascin-C (Tn3) were installed into the E3 ligase tripartite motif containing-21 (TRIM21) to redirect its degradation specificity. This was achieved via selection of naive yeast-displayed Tn3 libraries against two different oncogenic proteins associated with B-cell lymphomas, mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) and embryonic ectoderm development protein (EED), and replacing the native substrate-binding domain of TRIM21 with our evolved Tn3 domains. The resulting TRIM21-Tn3 fusion proteins retained the binding properties of the Tn3 as well as the E3 ligase activity of TRIM21. Moreover, we demonstrated that TRIM21- proteins through the ubiquitin proteasome system in cellular models. We explored the effects of binding domain avidity and E3 ligase utilization to gain insight into the requirements for targets.

3 April 2023
Verified
Other
Open access
JSJeffery S. Swers
Jeffery S. Swers
LGLuba Grinberg
Luba Grinberg
LWLin Wang
Lin Wang
HFHui Feng
Hui Feng
KLKristen Lekstrom
Kristen Lekstrom
MBManuel Baca
Manuel Baca
PDF file - 63K, Identification of BRAFV600E splice variant lacking exons 2-10 in dabrafenib resistant WMD009 tumour and derived cell line.

3 April 2023
Verified
Other
Open access
JSJeffery S. Swers
Jeffery S. Swers
LGLuba Grinberg
Luba Grinberg
LWLin Wang
Lin Wang
HFHui Feng
Hui Feng
KLKristen Lekstrom
Kristen Lekstrom
MBManuel Baca
Manuel Baca

3 April 2023
Verified
Other
Open access
JSJeffery S. Swers
Jeffery S. Swers
LGLuba Grinberg
Luba Grinberg
LWLin Wang
Lin Wang
HFHui Feng
Hui Feng
KLKristen Lekstrom
Kristen Lekstrom
MBManuel Baca
Manuel Baca
PDF file - 148K, Supplementary Figure S5: G6T8 and G6T6 have similar cytotoxic activity on TRAIL-sensitive cell lines.